Universidad Peruana Cayetano Heredia

Staphylococcus aureus bloodstream infections in Latin America: results of a multinational prospective cohort study

Mostrar el registro sencillo del ítem

dc.contributor.author Seas Ramos, Carlos Rafael
dc.contributor.author García Apac, Coralith Marlinda
dc.contributor.author Salles, M. J.
dc.contributor.author Labarca, J.
dc.contributor.author Luna, C.
dc.contributor.author Alvarez-Moreno, C.
dc.contributor.author Mejía-Villatoro, C.
dc.contributor.author Zurita, J.
dc.contributor.author Guzmán-Blanco, M.
dc.contributor.author Rodríguez-Noriega, E.
dc.contributor.author Reyes, J.
dc.contributor.author Arias, C. A.
dc.contributor.author Cárcamo Cavagnaro, César Paul Eugenio
dc.contributor.author Gotuzzo Herencia, José Eduardo
dc.date.accessioned 2018-03-22T23:38:48Z
dc.date.available 2018-03-22T23:38:48Z
dc.date.issued 2017
dc.identifier.uri https://hdl.handle.net/20.500.12866/1470
dc.description.abstract Background: Substantial heterogeneity in the epidemiology and management of Staphylococcus aureus bacteraemia (SAB) occurs in Latin America. We conducted a prospective cohort study in 24 hospitals from nine Latin American countries. Objectives: To assess the clinical impact of SAB in Latin America. Patients and methods: We evaluated differences in the 30 day attributable mortality among patients with SAB due to MRSA compared with MSSA involving 84 days of follow-up. Adjusted relative risks were calculated using a generalized linear model. Results: A total of 1030 patients were included. MRSA accounted for 44.7% of cases with a heterogeneous geographical distribution. MRSA infection was associated with higher 30 day attributable mortality [25% (78 of 312) versus 13.2% (48 of 363), adjusted RR: 1.94, 95% CI: 1.38–2.73, P < 0.001] compared with MSSA in the multivariable analysis based on investigators’ assessment, but not in a per-protocol analysis [13% (35 of 270) versus 8.1% (28 of 347), adjusted RR: 1.10, 95% CI: 0.75–1.60, P = 0.616] or in a sensitivity analysis using 30 day all-cause mortality [36% (132 of 367) versus 27.8% (123 of 442), adjusted RR: 1.09, 95% CI: 0.96–1.23, P = 0.179]. MRSA infection was not associated with increased length of hospital stay. Only 49% of MSSA bloodstream infections (BSI) received treatment with β-lactams, but appropriate definitive treatment was not associated with lower mortality (adjusted RR: 0.93, 95% CI: 0.70–1.23, P = 0.602). Conclusions: MRSA-BSIs in Latin America are not associated with higher 30 day mortality or longer length of stay compared with MSSA. Management of MSSA-BSIs was not optimal, but appropriate definitive therapy did not appear to influence mortality. en_US
dc.language.iso eng
dc.publisher Oxford University Press
dc.relation.ispartofseries Journal of Antimicrobial Chemotherapy
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject staphylococcus aureus en_US
dc.subject bacteremia en_US
dc.subject epidemiology en_US
dc.subject heterogeneity en_US
dc.subject follow-up en_US
dc.subject lactams en_US
dc.subject latin america en_US
dc.subject length of stay en_US
dc.subject prospective studies en_US
dc.subject mortality en_US
dc.subject methicillin-resistant staphylococcus aureus en_US
dc.subject bloodstream infections en_US
dc.subject methicillin-susceptible staphylococcus aureus en_US
dc.subject per protocol analysis en_US
dc.subject sensitivity analysis en_US
dc.subject methicillin-resistant staphylococcus aureus infection en_US
dc.title Staphylococcus aureus bloodstream infections in Latin America: results of a multinational prospective cohort study en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1093/jac/dkx350
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.08
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.01.05
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#1.06.01
dc.relation.issn 1460-2091


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas